SGLT2s cut heart failure hospitalizations, deaths in real-world trial

AstraZeneca plc (LSE:AZN; NYSE:AZN) said treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduced the risk of hospitalization for heart failure and all-cause mortality vs. other Type II diabetes therapies in a retrospective real-world study of more than 300,000 Type II diabetes patients. Data from the study, CVD-REAL, were reported March 19 at the American College of Cardiology meeting.

CVD-REAL included AZ's Farxiga dapagliflozin and two other SGLT2 inhibitors: Invokana canagliflozin from Johnson & Johnson (NYSE:JNJ) and Jardiance empagliflozin from Eli Lilly and Co. (NYSE:LLY) and Boehringer Ingelheim GmbH (Ingelheim, Germany)...